Studying a laser treatment for eye pressure in pigmentary glaucoma
Observes eye pressure after a laser treatment in people with pigmentary glaucoma.
Plain-language title generated from the registry record
Registry title: IOP Reduction in Pigmentary Glaucoma Using DSLT
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- Mann Eye InstituteHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Mann Eye Institute
- Trial code
- NCT07281391
- Record updated
- 9 April 2026
- Original description
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.Read full original descriptionShow less
Direct Selective Laser Trabeculoplasty Providing Effective Intraocular Pressure Reduction in Pigmentary Glaucoma Patients
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
Inclusion: Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss; Treatment naive, or washed out IOP ranging from ≥18-34 mmHg; Central corneal thickness (CCT) 480-600 µm; Able to complete medication washout and follow-up.
Exclusion: Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye; Prior laser trabeculoplasty <3 years; Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years; Patients anticipating cataract surgery within the follow-up period; History of ocular inflammation and infection; All other secondary glaucoma including exfoliative; Patients unable to have DSLT treatment.